Skip to main content

Robert W. Holloway, MD

Robert W. Holloway, MD

Medical Director (Gyn Onc), Gynecologic Oncologist

Cancer

Robert Holloway

Overview

Dr. Robert W. Holloway, MD is a board-certified gynecology oncologist in Orlando. Dr. Holloway joined the Florida Hospital Cancer Institute in 1994, and serves as the medical director of the Gynecologic Oncology Program. A graduate of Vanderbilt University School of Medicine, Dr. Holloway completed his OB/GYN residency at the University of Alabama at Birmingham and his fellowship in gynecologic oncology at Georgetown University in Washington, DC. Dr. Holloway is a Fellow of the American College of Surgeons. Additionally, Dr. Holloway is the principal investigator for several clinical trials and lectures regularly both nationally and internationally. His major research interests are robotic surgery and novel ovarian cancer therapies. Surgeons from around the world routinely attend his advanced training programs in robotic surgery.

Articles

Feasibility of a telemedicine lifestyle-based rehabilitation program (HEAL) for gynecologic cancer patients.

JOURNAL OF CLINICAL ONCOLOGY

2021

A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer

Gynecologic oncology

2021

Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety

CANCER MEDICINE

2021

Neoadjuvant chemotherapy followed by fertility sparing surgery in cervical cancers size 2-4 cm; emerging data and future perspectives

GYNECOLOGIC ONCOLOGY

2021

Intratubal Pseudopapillary Histiocytic Hyperplasia: A New Histologic Variant in the Spectrum of Histiocytic Lesions Involving the Fallopian Tube

INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY

2021

Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

2021

Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat?

GYNECOLOGIC ONCOLOGY

2021

Predicted Immunogenicity of CDK12 Biallelic Loss-of-Function Tumors Varies across Cancer Types

JOURNAL OF MOLECULAR DIAGNOSTICS

2021

Carcinomatosis in Early-Stage Cervical Cancer Treated with Robotic Radical Hysterectomy: Recurrence Patterns, Risk Factors, and Survival

ANNALS OF SURGICAL ONCOLOGY

2021

ASO Visual Abstract: Carcinomatosis in Early-Stage Cervical Cancer Treated with Robotic Radical Hysterectomy-Recurrence Patterns, Risk Factors, and Survival

ANNALS OF SURGICAL ONCOLOGY

2021

Education & Training

Education

Vanderbilt University Medical Center

Residency

University of Alabama Birmingham

Fellowship

Georgetown University Hospital

Specialty

Gynecology Oncology

Board Certifications

American Board of Obstetrics & Gynecology